Oncopeptides secures fast-track designation for Window-of-Opportunity study in glioblastoma

CAR-T Digest - August 2020

09 March 2026: Oncopeptides secures fast-track designation for Window-of-Opportunity study in glioblastoma

Oncopeptides announced that it has secured fast-track designation in Norway for a planned Window-of-Opportunity clinical study evaluating a peptide drug conjugate in glioblastoma, following regulatory agreement on the study design with both the Swedish and Norwegian medical authorities
The study will represent the first clinical evaluation of the company’s peptide drug conjugate platform in glioblastoma, marking a strategic expansion of the technology beyond its current focus in multiple myeloma
The trial is designed as a small proof-of-concept study involving approximately 10 patients and will use an already approved Oncopeptides drug to rapidly evaluate brain penetration and tumor distribution, helping validate the platform’s ability to cross the blood-brain barrier
Fast-track designation from the Norwegian regulator will enable an accelerated review of the upcoming clinical trial application, reflecting the urgent need for new therapies in glioblastoma, one of the most aggressive brain cancers with limited treatment options and a median survival of only 12–15 months
If successful, the study is expected to generate early clinical evidence supporting further development of peptide drug conjugates in glioblastoma, potentially opening a new pathway for targeted therapies in a disease area with significant unmet medical need